Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
This is an open-label, dose-escalation/dose-expansion, phase I clinical trial study to
investigate the safety, tolerability, and efficacy of HWH340. In addition, the
pharmacokinetic characteristics will also be investigated. Three parts are included in this
study.
Phase:
Phase 1
Details
Lead Sponsor:
Hubei Biological Medicine Industrial Technology Institute Co., Ltd.